Synlogic, Inc. (SYBX)

US — Healthcare Sector
Peers: EFTR  GRTX  ICVX  ACIU  TARA  VCNX  MNPR  MIRO  SRZN  GLUE  STOK  ANTX  PASG  FDMT  GBIO  KRON  ERAS  CCCC  EWTX  CMRA  SABS  PCSA  FRTX  THRD 

Automate Your Wheel Strategy on SYBX

With Tiblio's Option Bot, you can configure your own wheel strategy including SYBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SYBX
  • Rev/Share 0.0
  • Book/Share 1.0659
  • PB 1.1446
  • Debt/Equity 0.0
  • CurrentRatio 3.6766
  • ROIC -0.2286

 

  • MktCap 14269242.0
  • FreeCF/Share -1.4199
  • PFCF -0.8181
  • PE 10.004
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.1091

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Synlogic, Inc. (SYBX)

  • IPO Date 2015-09-30
  • Website https://www.synlogictx.com
  • Industry Biotechnology
  • CEO Ms. Mary Beth Dooley
  • Employees 1
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.